From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q2 2017 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑的候选者”转变为“已获批准、指定、列入、合格、注册、报销或预先授权的选择”,从而进入买家自身的采购、报销、配方、规格、采购、网络、目录或计划系统,使得公司未来业务的重要部分可以在没有每次单独销售事件的情况下到达。同时,管理层是否传达这种准入状态是新的,以至于它解锁的大部分量仍在前方,而报告的结果只捕捉了其中一小部分。 在记录中,管理层讨论了各种分销渠道、产品发布、机构管道等。具体提到: - 日本机构市场:提到“我们开始看到更多活动”,但这是否意味着已进入系统? - DCIO渠道:提到“结果温和”,但“我们实现了许多目标,关于定位产品、进入平台、进入推荐列表”,并提到“绿色芽”但“尚不实质性”。 - 欧洲:提到“看到真正的牵引力”,但未明确说明已进入系统。 - 关于产品:提到“低久期优先基金”等,但未明确说进入系统。 - 关于基础设施:提到“我们正在创建目标组合”,但未说已进入系统。 关键点:管理层没有明确描述公司已进入任何具体的买方系统(如批准供应商名单、处方集、网络等)。他们谈论的是分销努力、产品定位、平台准入,但这些都是常规销售关系的一部分。没有提到“已获批准”、“已列入”、“已合格”等具体状态。也没有提到这种状态是新的,并且未来流量将增加。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.